AI RESEARCH
Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability
arXiv CS.LG
•
ArXi:2604.05478v1 Announce Type: cross Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.